Boston Scientific Corporation $BSX Stock Holdings Lifted by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd increased its position in Boston Scientific Corporation (NYSE:BSX) by 621.0% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 450,271 shares of the medical equipment provider’s stock after buying an additional 387,819 shares during the quarter. Boston Scientific makes up about 0.5% of Y Intercept Hong Kong Ltd’s investment portfolio, making the stock its 9th largest position. Y Intercept Hong Kong Ltd’s holdings in Boston Scientific were worth $28,255,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Boston Scientific by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after acquiring an additional 1,436,550 shares in the last quarter. State Street Corp grew its position in shares of Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after purchasing an additional 920,495 shares in the last quarter. Capital World Investors raised its stake in Boston Scientific by 1.9% during the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares during the period. Norges Bank bought a new stake in Boston Scientific during the 4th quarter valued at approximately $2,199,395,000. Finally, Morgan Stanley lifted its holdings in Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after purchasing an additional 2,246,308 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BSX. Wolfe Research lowered shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Wells Fargo & Company reissued an “equal weight” rating and issued a $55.00 target price (down from $75.00) on shares of Boston Scientific in a report on Thursday, May 28th. Barclays cut their target price on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research note on Thursday, May 28th. Leerink Partners reduced their price target on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a report on Thursday, May 28th. Finally, Oppenheimer set a $90.00 price target on shares of Boston Scientific in a research note on Thursday, April 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $83.36.

Boston Scientific Stock Up 4.7%

Shares of BSX opened at $45.09 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock has a market capitalization of $67.01 billion, a price-to-earnings ratio of 18.86, a price-to-earnings-growth ratio of 0.82 and a beta of 0.58. Boston Scientific Corporation has a 1 year low of $42.25 and a 1 year high of $109.50. The business’s 50 day simple moving average is $51.39 and its 200-day simple moving average is $69.60.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period last year, the firm posted $0.75 earnings per share. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its board has authorized a stock buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s board believes its stock is undervalued.

Insiders Place Their Bets

In other Boston Scientific news, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Cheryl Pegus bought 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares in the company, valued at approximately $99,987.30. The trade was a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 9,800 shares of company stock valued at $554,012 in the last three months. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.